Prophylactic HPV vaccination in HPV‐related gynecologic cancers: European Society of Gynecological Oncology (ESGO) prevention committee opinion
Authors:
Open Access
- 30 December 2024
- journal article
- research article
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 169 (2) , 597-604
Abstract
Many clinicians recommend that patients diagnosed with HPV‐related gynecologic cancers receive prophylactic HPV vaccination at the time of cancer diagnosis or after cancer treatment. In view of the large use of such practice, we aimed to assess the literature evidence supporting the use of prophylactic HPV vaccines after diagnosis or treatment of HPV‐related gynecologic cancers. Women who develop HPV‐related cervical, vaginal, and vulvar cancers represent a subgroup of patients who may be particularly sensitive to HPV infection and re‐acquire infections. The rationale that the use of prophylactic HPV vaccination at the time or after treatment for cervical, vaginal, and vulvar cancers might reduce the risk of future HPV‐related diseases might be explained by the data coming from the use of HPV vaccination after treatment of pre‐invasive disease; however, the evidence on the use of HPV vaccination in the setting of HPV‐related gynecologic cancers is currently absent. In this context, observational and experimental studies document an important drop in effectiveness of HPV vaccination by age. Physicians should be aware of catch‐up programs in their countries and should be ready to counsel patients about prophylactic HPV vaccine efficacy according to their age. In general, no evidence exists supporting the use of prophylactic HPV vaccine in patients diagnosed with HPV‐related gynecologic cancers; therefore, the European Society of Gynecological Oncology (ESGO) prevention committee opinion is to counsel these patients as any HPV‐related non‐gynecologic cancer (such as anal or oropharyngeal cancer) and non‐cancer patient, suggesting vaccination according to patient's age and prognosis, knowing there is a decrease of efficacy with increasing age. Studies on the use of prophylactic HPV vaccine in patients diagnosed with HPV‐related gynecologic cancers are strongly needed.Keywords
This publication has 48 references indexed in Scilit:
- Efficacy and immunogenicity of AS04‐HPV‐16/18 vaccine in females with existing cervical HR‐HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwideInternational Journal of Cancer, 2024
- Implementation barriers and considerations for recommending and administering the human papillomavirus (HPV) vaccination in oncology settingsJournal of Cancer Survivorship, 2023
- Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factorCancer, 2021
- The European response to the WHO call to eliminate cervical cancer as a public health problemInternational Journal of Cancer, 2020
- Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literatureAnnals of Oncology, 2020
- Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination statusInternational Journal of Cancer, 2019
- Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus–Associated CancersJAMA Network Open, 2018
- Safety of Human Papillomavirus Vaccines: An Updated ReviewDrug Safety, 2017
- Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trialInternational Journal of Cancer, 2016
- Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasiaInternational Journal of Cancer, 2009